MedPath

Lorazepam

Generic Name
Lorazepam
Brand Names
Ativan, Loreev
Drug Type
Small Molecule
Chemical Formula
C15H10Cl2N2O2
CAS Number
846-49-1
Unique Ingredient Identifier
O26FZP769L
Background

Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic. It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm.

Indication

Lorazepam is FDA-approved for the short-term relief of anxiety symptoms related to anxiety disorders and anxiety associated with depressive symptoms such as anxiety-associated insomnia. It is as well used as an anesthesia premedication in adults to relieve anxiety or to produce sedation/amnesia and for the treatment of status epilepticus.

Some off-label indications of lorazepam include rapid tranquilization of an agitated patient, alcohol withdrawal delirium, alcohol withdrawal syndrome, muscle spasms, insomnia, panic disorder, delirium, chemotherapy-associated anticipatory nausea and vomiting, and psychogenic catatonia.

Associated Conditions
Agitation, Alcohol Withdrawal Delirium, Alcohol Withdrawal Syndrome, Anxiety, Anxiety Disorders, Chemotherapy-Induced Nausea and Vomiting, Delirium, Insomnia, Muscle Spasms, Panic Disorder, Psychogenic Catatonia, Status Epilepticus
Associated Therapies
Anesthetic premedication therapy

Meth-OD: A Study of IXT-m200 in Patients With Toxicity From Methamphetamine Overdose

Phase 2
Terminated
Conditions
Methamphetamine Intoxication (Disorder)
Interventions
First Posted Date
2021-01-20
Last Posted Date
2023-11-18
Lead Sponsor
InterveXion Therapeutics, LLC
Target Recruit Count
20
Registration Number
NCT04715230
Locations
🇺🇸

University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

🇺🇸

Sacred Heart Medical Center, Spokane, Washington, United States

🇺🇸

University of New Mexico Hospital, Albuquerque, New Mexico, United States

and more 1 locations

Lorazepam Effects on Neuroimaging Measures

Early Phase 1
Withdrawn
Conditions
Lorazepam
Neuroimaging
Interventions
First Posted Date
2020-12-17
Last Posted Date
2022-05-27
Lead Sponsor
Northwell Health
Registration Number
NCT04671836
Locations
🇺🇸

The Zucker Hillside Hospital, Glen Oaks, New York, United States

Lorazepam for the Analgosedation of Pediatric Patients in Mechanical Ventilation.

Phase 2
Conditions
Analgesia
Interventions
First Posted Date
2020-11-27
Last Posted Date
2020-11-27
Lead Sponsor
Bambino Gesù Hospital and Research Institute
Target Recruit Count
9
Registration Number
NCT04646135

Multimodal Analgesia Effect on Post Surgical Patient

First Posted Date
2020-01-27
Last Posted Date
2025-03-21
Lead Sponsor
University of California, Davis
Target Recruit Count
60
Registration Number
NCT04240626
Locations
🇺🇸

UC Davis Health, Sacramento, California, United States

Phenobarbital vs Ativan for Alcohol Withdrawal in the Intensive Care Unit

Phase 4
Conditions
Alcohol Withdrawal
Alcohol Withdrawal Delirium
Interventions
First Posted Date
2019-11-07
Last Posted Date
2020-10-08
Lead Sponsor
OSF Healthcare System
Target Recruit Count
142
Registration Number
NCT04156464
Locations
🇺🇸

OSF Saint Francis Medical Center, Peoria, Illinois, United States

Multi-modal Assessment of Gamma-aminobutyric Acid (GABA) Function in Psychosis

Phase 4
Completed
Conditions
Schizophrenia
Bipolar Disorder
Healthy
Psychosis
Schizophreniform Disorders
Schizo Affective Disorder
Major Depression With Psychotic Features
Interventions
Other: Placebo and fMRI
First Posted Date
2019-07-02
Last Posted Date
2025-03-13
Lead Sponsor
University of Michigan
Target Recruit Count
143
Registration Number
NCT04004416
Locations
🇺🇸

University of Michigan, Ann Arbor, Michigan, United States

LORA-PITA IV General Investigation

Completed
Conditions
Status Epilepticus
Interventions
First Posted Date
2019-04-05
Last Posted Date
2025-03-10
Lead Sponsor
Pfizer
Target Recruit Count
206
Registration Number
NCT03905798
Locations
🇯🇵

Pfizer Local Country office, Tokyo, Shibuya-ku, Japan

Effects of Oxytocin and Lorazepam on Fear-related Intra-amygdalar Activity

Phase 1
Completed
Conditions
Oxytocin, Lorazepam, Anti-Anxiety Agents, Physiological Effects of Drugs
Interventions
Drug: Placebo nasalspray
Drug: Placebo Oral Tablet
First Posted Date
2019-02-04
Last Posted Date
2019-04-17
Lead Sponsor
University Hospital, Bonn
Target Recruit Count
120
Registration Number
NCT03829839
Locations
🇩🇪

Department of Psychiatry, University of Bonn, Bonn, Germany

Alcohol Withdrawal Syndrome Treated With Adjunctive Phenobarbital or Ketamine

Phase 4
Withdrawn
Conditions
Alcohol Withdrawal Syndrome
Interventions
First Posted Date
2018-12-28
Last Posted Date
2019-09-19
Lead Sponsor
Santa Barbara Cottage Hospital
Registration Number
NCT03788889

Benzodiazepines for the Reduction of Distress and Pain During and After Emergency Department Care

Phase 2
Terminated
Conditions
Acute Pain
Interventions
Drug: Placebos
First Posted Date
2018-11-28
Last Posted Date
2020-03-09
Lead Sponsor
Maria Pacella
Target Recruit Count
1
Registration Number
NCT03756038
Locations
🇺🇸

UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania, United States

🇺🇸

UPMC Mercy Hospital, Pittsburgh, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath